Business Context and Reporting Period
Company: MDxHealth SA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2024 (Interim Report for the period ended August 21, 2024)
Principal Executive Office: Herstal, Belgium
This filing incorporates the Company's 2024 Interim Report, a press release dated August 21, 2024, and two amendments to the Company's Credit Agreement with affiliates of OrbiMed.
Key Financial Metrics
The provided text serves as a cover sheet and index for the Form 6-K. It does not contain the detailed financial tables or specific numerical data from the attached 2024 Interim Report (Exhibit 99.1). Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Credit Agreement Amendments: The Company executed two amendments to its Credit Agreement with OrbiMed affiliates:
- First Amendment dated July 30, 2024 (Exhibit 4.1).
- Second Amendment dated August 20, 2024 (Exhibit 4.2).
- Confidentiality: Certain portions of the Credit Agreement amendments were redacted as confidential and competitively harmful.
Guidance, Outlook, and Risks
The cover text does not include specific management commentary, forward-looking guidance, or a detailed risk factor analysis. The press release (Exhibit 99.2) is furnished but not deemed "filed" for liability purposes under Section 18 of the Exchange Act, though it is incorporated by reference into specific Registration Statements on Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 (2024 Interim Report) for actual financial performance metrics (revenue, EBITDA, cash position) which are not present in the cover text.
- Examine Exhibits 4.1 and 4.2 to understand the specific terms, covenants, and financial implications of the Credit Agreement amendments with OrbiMed.
- Read Exhibit 99.2 (Press Release) for qualitative updates on business operations and strategic direction.
- Verify the impact of the redacted confidential portions in the Credit Agreement amendments on future financing flexibility.